Inhibitor Development in Patients With Hemophilia: An Overview

Seminars in Hematology

Volumn 43, Issue SUPPL. 4, 2006, Pages

  Leissinger, Cindy A ^a  

^a TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIGEN BINDING; BLEEDING; EDITORIAL; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; TREATMENT FAILURE;

EID: 33646247609     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.03.002     Document Type: Editorial

References (15)

1. Evans G.L., and Morgan R.A. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci U S A 95 (1998) 5734-5739
2. Kasper C.K. Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians. Treatment of Hemophilia Monograph Series, No. 34 (2004), World Federation of Hemophilia, Montreal, Québec, Canada
3. Scharrer I., Bray G.L., and Neutzling O. Incidence of inhibitors in haemophilia A patients-A review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 5 (1999) 145-154
4. Key N.S. Inhibitors in congenital coagulation disorders. Br J Haematol 127 (2004) 379-391
5. Young G., McDaniel M., and Nugent D.J. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 11 (2005) 203-207
6. DiMichele D., Rivard G., Hay C., and Antunes S. Inhibitors in haemophilia. Clinical aspects. Haemophilia 10 suppl 4 (2004) 140-145
7. Darby S.C., Keeling D.M., Spooner R.J., Wan Kan S., Giangrande P.L., Collins P.W., et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2 (2004) 1047-1054
8. DiMichele D. Immune tolerance therapy dose as an outcome predictor. Haemophilia 9 (2003) 382-386
9. DiMichele D.M., Kroner B.L., and North American Immune Tolerance Study Group. The North American Immune Tolerance Registry. Practices, outcomes, outcome predictors. Thromb Haemost 87 (2002) 52-57
10. DiMichele D. Inhibitors. Resolving diagnostic and therapeutic dilemmas. Haemophilia 8 (2002) 280-287
11. Hay C.R., Baglin T.P., Collins P.W., Hill F.G., and Keeling D.M. The diagnosis and management of factor VIII and IX inhibitors. A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 111 (2000) 78-90
12. Warrier I., Ewenstein B.M., Koerper M.A., Shapiro A., Key N., DiMichele D., et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 19 (1997) 23-27
13. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 5 suppl 3 (1999) 11-17
14. Ross-Degnan D., Soumerai S.B., Avorn J., Bohn R.L., Bright R., and Aledort L.M. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care 11 (1995) 327-344
15. Chang H., Sher G.D., Blanchette V.S., and Teitel J.M. The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia 5 (1999) 247-252